Author(s): Hankins JS; Brambilla D; Potter MB; Kutlar A; Gibson RW; King AA; Baumann AA; Melvin CL; Gordeuk VR; Hsu LL; Nwosu C; Porter JS; Alberts NM; Badawy SM; Simon J; Glassberg J; Lottenberg R; DiMartino L; Jacobs S; Fernandez ME; Bosworth H; ...

Hydroxyurea reduces sickle cell disease (SCD) complications, but medication adherence is low. We tested two mobile health (mHealth) interventions targeting determinants of low adherence among patients (InCharge Health) and low prescribing among providers (HU Toolbox) in a multi-center non-randomi ...

Article GUID: 37738155

Author(s): Pizzo A; Porter JS; Carroll Y; Burcheri A; Smeltzer MP; Beestrum M; Nwosu C; Badawy SM; Hankins JS; Klesges LM; Alberts NM;

Sickle cell disease (SCD) is an inherited red blood cell disorder associated with frequent painful events and organ damage. Hydroxyurea (HU) is the recommended evidence-based treatment of SCD. However, among patients eligible for HU, prescription rates are low. Utilizing a scoping review approach ...

Article GUID: 37691131

Author(s): Keenan ME, Loew M, Berlin KS, Hodges J, Alberts NM, Hankins JS, Porter JS

OBJECTIVE: Determining how the health-related quality of life (HRQOL) is impacted by living with Sickle Cell Disease (SCD) can inform psychosocial interventions. The purpose of the present study is to determine if demographic and treatment variables predict membership into empirically derived subgroups of HRQOL among youth and young adults with SCD. METHO ...

Article GUID: 33249456